Table 2.
Treatments and outcomes.
| n = 34 | |
|---|---|
| First line therapy | |
| PAD | 2 (5.9%) |
| VD | 1 (2.9%) |
| VRD | 15 (44.1%) |
| VTD | 16 (47.1%) |
| Auto-HSCT | |
| Single/tandem | 28 (82%)/6 (18%) |
| Post-HSCT treatment | 12/34 (35.3%) |
| Daratumumab + RD | 2 (16.7%) |
| Lenalidomide | 5 (41.6%) |
| VTD/VRD | 2 (16.7%) |
| >2 lines | 3 (25%) |
| Maintenance treatment | 19/34 (55.9%) |
| Relapse | 7/34 (20.6%) |
| Best response | |
| SD | 2 (5.9%) |
| PR | 2 (5.9%) |
| VgPR | 9 (26.5%) |
| CR/sCR | 21 (61.7%) |
| Deaths | 9 (26.5%) |
| Median follow-up, months (range) | 42.4 (10.4–103.9) |
Abbreviations. PAD, bortezomib, dexamethasone, and doxorubicin; VD, bortezomib and dexamethasone; VRD, bortezomib, lenalidomide, and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone; HSCT, hematopoietic stem cell transplantation; auto-HSCT, autologous HSCT; RD, lenalidomide and dexamethasone; SD, stable disease; PR, partial remission; VgPR, very good partial remission; CR, complete remission; sCR, stringent CR.